

Fatih Arslan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/765132/publications.pdf>

Version: 2024-02-01

55
papers

7,430
citations

201385

27
h-index

182168

51
g-index

58
all docs

58
docs citations

58
times ranked

11291
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. <i>Stem Cell Research</i> , 2010, 4, 214-222.	0.3	1,831
2	Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. <i>Stem Cell Research</i> , 2013, 10, 301-312.	0.3	932
3	Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. <i>Stem Cell Research</i> , 2008, 1, 129-137.	0.3	531
4	Prognostic Value of Fractional Flow Reserve. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1641-1654.	1.2	513
5	Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. <i>Stem Cell Research</i> , 2011, 6, 206-214.	0.3	379
6	Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. <i>Journal of Translational Medicine</i> , 2011, 9, 47.	1.8	323
7	Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti-Toll-Like Receptor-2 Antibody. <i>Circulation</i> , 2010, 121, 80-90.	1.6	319
8	Innate immune signaling in cardiac ischemia. <i>Nature Reviews Cardiology</i> , 2011, 8, 292-300.	6.1	278
9	Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. <i>Basic Research in Cardiology</i> , 2012, 107, 270.	2.5	277
10	The innate immune response in reperfused myocardium. <i>Cardiovascular Research</i> , 2012, 94, 276-283.	1.8	224
11	Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1664-1671.	2.9	224
12	The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. <i>European Heart Journal</i> , 2017, 38, ehw247.	1.0	222
13	TLR2 and TLR4 in Ischemia Reperfusion Injury. <i>Mediators of Inflammation</i> , 2010, 2010, 1-8.	1.4	152
14	Lack of Fibronectin-EDA Promotes Survival and Prevents Adverse Remodeling and Heart Function Deterioration After Myocardial Infarction. <i>Circulation Research</i> , 2011, 108, 582-592.	2.0	149
15	Derivation and characterization of human fetal MSCs: An alternative cell source for large-scale production of cardioprotective microparticles. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 1215-1224.	0.9	137
16	Danger Signals in the Initiation of the Inflammatory Response after Myocardial Infarction. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	1.4	101
17	Treatment With OPN-305, a Humanized Anti-Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 279-287.	1.4	95
18	Intracoronary Infusion of Allogeneic Mesenchymal Precursor Cells Directly After Experimental Acute Myocardial Infarction Reduces Infarct Size, Abrogates Adverse Remodeling, and Improves Cardiac Function. <i>Circulation Research</i> , 2013, 113, 153-166.	2.0	92

#	ARTICLE	IF	CITATIONS
19	Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2008, 14, 1205-1216.	0.9	77
20	Endogenous Inflammatory Molecules Engage Toll-Like Receptors in Cardiovascular Disease. <i>Journal of Innate Immunity</i> , 2010, 2, 307-315.	1.8	67
21	Targeting danger-associated molecular patterns after myocardial infarction. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 223-239.	1.5	48
22	2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. <i>Netherlands Heart Journal</i> , 2018, 26, 417-421.	0.3	48
23	Metabolic Adaptation to a Disruption in Oxygen Supply during Myocardial Ischemia and Reperfusion Is Underpinned by Temporal and Quantitative Changes in the Cardiac Proteome. <i>Journal of Proteome Research</i> , 2012, 11, 2331-2346.	1.8	46
24	Coronary artery aneurysms, insights from the international coronary artery aneurysm registry (CAAR). <i>International Journal of Cardiology</i> , 2020, 299, 49-55.	0.8	46
25	Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group. <i>Netherlands Heart Journal</i> , 2020, 28, 116-130.	0.3	42
26	Unraveling Pleiotropic Effects Of Statins. <i>Circulation Research</i> , 2008, 103, 334-336.	2.0	33
27	Quantitative T ₂ mapping of the mouse heart by segmented MLEV phase-cycled T ₂ preparation. <i>Magnetic Resonance in Medicine</i> , 2014, 72, 409-417.	1.9	30
28	Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. <i>Scientific Reports</i> , 2017, 7, 9193.	1.6	23
29	Myocardial blush grade: a predictor for major adverse cardiac events after primary PTCA with stent implantation for acute myocardial infarction. <i>Acta Cardiologica</i> , 2007, 62, 445-451.	0.3	21
30	Statins Promote Cardiac Infarct Healing by Modulating Endothelial Barrier Function Revealed by Contrast-Enhanced Magnetic Resonance Imaging. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 186-194.	1.1	20
31	Assessment of Myocardial Fibrosis in Mice Using a T ₂ *-Weighted 3D Radial Magnetic Resonance Imaging Sequence. <i>PLoS ONE</i> , 2015, 10, e0129899.	1.1	19
32	Quantitative T ₂ * assessment of acute and chronic myocardial ischemia/reperfusion injury in mice. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2012, 25, 369-379.	1.1	18
33	Lack of haptoglobin results in unbalanced VEGF±/angiopoietin-1 expression, intramural hemorrhage and impaired wound healing after myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 56, 116-128.	0.9	15
34	Virtual support for remote proctoring in TAVR during COVID-19. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E733-E736.	0.7	14
35	²³ Na chemical shift imaging and Gd enhancement of myocardial edema. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 343-354.	0.7	11
36	2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation. <i>Netherlands Heart Journal</i> , 2021, 29, 557-565.	0.3	9

#	ARTICLE	IF	CITATIONS
37	Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice. <i>Scientific Reports</i> , 2017, 7, 18039.	1.6	8
38	Danger Signals in Cardiovascular Disease. <i>Mediators of Inflammation</i> , 2014, 2014, 1-2.	1.4	7
39	Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. <i>European Journal of Heart Failure</i> , 2017, 19, 1732-1735.	2.9	6
40	Indications for an early invasive strategy in NSTEMI-ACS patients. <i>Netherlands Heart Journal</i> , 2020, 28, 131-135.	0.3	6
41	Ventricular TLR4 Levels Abrogate TLR2-Mediated Adverse Cardiac Remodeling upon Pressure Overload in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11823.	1.8	6
42	Contrast-Enhanced T1-Mapping MRI for the Assessment of Myocardial Fibrosis. <i>Current Cardiovascular Imaging Reports</i> , 2014, 7, 1.	0.4	5
43	Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs. <i>Clinical Research in Cardiology</i> , 2021, 111, 105.	1.5	5
44	The management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: early invasive strategy for all?. <i>Netherlands Heart Journal</i> , 2017, 25, 170-172.	0.3	4
45	Guidance of interventions in structural heart disease; three-dimensional techniques are here to stay. <i>Netherlands Heart Journal</i> , 2017, 25, 63-64.	0.3	3
46	Acute pontine infarction after percutaneous coronary intervention: a very rare but devastating complication. <i>Netherlands Heart Journal</i> , 2015, 23, 366-367.	0.3	1
47	Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2016, 221, 682-687.	0.8	1
48	Percutaneous coronary intervention for chronic total coronary occlusion: Do. Or do not. There is no try. <i>Netherlands Heart Journal</i> , 2021, 29, 1-3.	0.3	1
49	Sex differences in treatment strategy for coronary artery aneurysms: Insights from the international Coronary Artery Aneurysm Registry. <i>Netherlands Heart Journal</i> , 2022, 30, 328-334.	0.3	1
50	Mediators of inflammation after cardiac ischemia: The role of invariant natural killer T (iNKT) cells. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 63, 118-121.	0.9	0
51	Highlights of Keystone symposium "Fibrosis: from bench to bedside"™. <i>Fibrogenesis and Tissue Repair</i> , 2014, 7, .	3.4	0
52	Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 488-492.	0.7	0
53	Hypertension as a predictor of adverse cardiac events in patients with borderline fractional flow reserve.. <i>Acta Cardiologica</i> , 2007, 62, 367-372.	0.3	0
54	Multiple culprit lesions in ST-segment elevation myocardial infarction with cardiogenic shock: a case of simultaneous thrombosis of two infarct-related arteries. <i>Netherlands Heart Journal</i> , 2022, , 1.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Actual management costs of patients with non-valvular atrial fibrillation treated with percutaneous left atrial appendage closure or oral anticoagulation. International Journal of Cardiology, 2022, 351, 61-64.	0.8	0